Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

pharma companies in oncology

Pharmaceutical intelligence for pharma companies in oncology with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
0
Assets
2

Recent signals(3)

ClinicalAugust 5, 2026

VR Program for Heart Health Education in Breast Cancer Survivors Undergoing Treatment

A study is underway to evaluate VR program aimed at improving heart health knowledge among breast cancer survivors receiving anthracyclines or trastuzumab.

ClinicalJuly 18, 2026

NCI Launches Biospecimen Study to Enhance Immunotherapy Research

The National Cancer Institute is conducting a study to collect biospecimens from cancer patients to improve treatment understanding.

ClinicalJuly 9, 2026

NCI Launches Study on Outcomes and Risks of Rare CNS Tumors

The National Cancer Institute is conducting a study to assess outcomes and risks in patients with 12 rare CNS tumors.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(3)

ClinicalAugust 5, 2026

VR Program for Heart Health Education in Breast Cancer Survivors Undergoing Treatment

A study is underway to evaluate VR program aimed at improving heart health knowledge among breast cancer survivors receiving anthracyclines or trastuzumab.

ClinicalJuly 18, 2026

NCI Launches Biospecimen Study to Enhance Immunotherapy Research

The National Cancer Institute is conducting a study to collect biospecimens from cancer patients to improve treatment understanding.

ClinicalJuly 9, 2026

NCI Launches Study on Outcomes and Risks of Rare CNS Tumors

The National Cancer Institute is conducting a study to assess outcomes and risks in patients with 12 rare CNS tumors.

Competitive activity

No signals indexed for this entity yet.

Assets

NCI →
trastuzumab →

Therapeutic areas

Breast Cancer →
CNS Tumors →
Immunotherapy →
Oncology →

Indications

Breast Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.